We compared factor VII clotting activity (FVIIc) assays using different thromboplastins to determine which is the most sensitive for activated FVII (FVIIa) or for FVII antigen (FVIIag). FVIIc levels were measured using thromboplastins derived from bovine brain (FVIIc Bov), human placenta (FVIIc Hum), and rabbit brain (FVIIc Rab). FVIIa levels were measured by fluorogenic assays using human soluble tissue factor (rsTF) or bovine rsTF. We also measured FVII activity by an amidolytic assay (FVIIc:am Hum) using human thromboplastin and a chromogenic substrate for thrombin. FVIIag levels were determined by ELISA. In the FVIIa assay, the reaction time obtained from using bovine rsTF was shorter than that with human rsTF, suggesting that the interaction of plasma FVIIa with bovine rsTF was stronger than with human rsTF. The plasma FVIIa levels measured using human rsTF and bovine rsTF were almost the same (r=0.947, p<0.0001). Among the three FVIIc assays, FVIIc Bov had the strongest positive correlation with the plasma FVIIa level (r=0.886, p<0.000l), but had no correlation with FVIIag. An increase of 1 ng/ml in the plasma FVIIa level yielded a 27.9% increase of FVIIc Bov. Plasma FVIIc Hum and FVIIc:am Hum showed moderate correlations with both FVIIa (r=0.520, p<0.02 and r=0.569, p<0.01, respectively) and FVIIag (r=0.438, p<0.05 and r=0.468, p<0.05, respectively). FVIIc Rab had the lowest correlation with FVIIa (r=0.367, p<0.1), but had a moderate correlation with FVIIag (r=0.436, p<0.05). After in vitro cold activation, FVIIc Bov levels increased the most and FVIIc:am levels showed the least change. These findings indicate that consideration of the thromboplastin used for assay is necessary when assessing the clinical significance of FVII activity as a cardiovascular risk factor.
References
1
Meade TW,
Mellows S,
Brozovic M,
Miller GJ,
Chakrabarti RR,
North WR S,
Haines A,
Stirling Y,
Imeson JD,
Thompson SG.
Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537
2
Meade TW,
Ruddock V,
Stirling Y,
Chakrabarti R,
Miller GJ.
Fibrinolytic activity, clotting factors and long-term incidence of ischaemic Heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079
4
Heinrich J,
Balleisen L,
Schulte H,
Assmann G,
van de Loo J.
Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM Study in healthy men Arterioscler Thromb 1994; 14: 54-59
5
Cortellaro M,
Boschetti C,
Cofrancesco E,
Zanussi C,
Catalano M,
de Gaetano G,
Gabrielli L,
Lombardi B,
Specchia G,
Tavazzi L,
Tremoli E,
della Volpe A,
Polli E.
The PLAT study group.
The PLAT study: Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results Arterioscler Thromb 1992; 12: 1063-1070
6
Banerjee AK,
Pearson J,
Gilliland EL,
Gross D,
Lewis JD,
Stirling Y,
Meade TW.
A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost 1992; 68: 261-263
7
Orlando M,
Leri O,
Macioce G,
Mattia G,
Ferri GM.
Factor VII in subjects at risk for thromboembolism: activation or increased synthesis ?. Haemostasis 1987; 17: 340-343
8
Carvalho de Sousa J,
Azevedo J,
Soria C,
Barros F,
Ribeiro C,
Parreira F,
Caen JP.
Factor VII hyperactivity in acute myocardial thrombosis. A relation to the coagulation activation Thromb Res 1988; 51: 165-173
10
Takano K,
Yamaguchi T,
Okada Y,
Uchida K,
Kisiel W,
Kato H.
Hypercoagulability in acute ischemic stroke: Analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method. Thromb Res 1990; 58: 481-491
12
Suzuki T,
Yamauchi K,
Matsushita T,
Furumichi T,
Furui H,
Tsuzuki J,
Saito H.
Elevation of factor VII activity and mass in coronary artery disease of varying severity. Clin Cardiol 1991; 14: 731-736
15
Vaziri ND,
Kennedy SC,
Kennedy D,
Gonzales E.
Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris. Am J Med 1992; 93: 651-657
16
Folsom AR,
Wu KK,
Shahar E,
Davis CE.
Atherosclerosis Risk in Communities (ARIC) Investigator.
Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb 1993; 13: 1829-1836
17
Miller GJ,
Stirling Y,
Esnouf MP,
Heinrich J,
van de Loo J,
Kienast J,
Wu KK,
Morrissey JH,
Meade TW,
Martin JC,
Imeson JD,
Cooper JA,
Finch A.
Factor VH-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: An international study. Thromb Haemost 1994; 71: 38-48
18
Kario K,
Nago N,
Kuroda T,
Kayaba K,
Saegusa T,
Matsuo H,
Tsutusmi A,
Matsuo T,
Shimada K.
Characteristics of the insulin resistance syndrome in a Japanese population: The Jichi Medical Cohort Study, (submitted).
19
Miller GJ,
Walter SJ,
Stirling Y,
Thompson SG,
Esnouf MP,
Meade TW.
Assay of factor VII activity by two techniques; evidence for increased conversion of VII to Vila in hyperlipidemia, which possible implications for ischaemic heart disease. Br J Haematol 1985; 59: 249-258
20
Seligsohn U,
Østerud B,
Rapaport SI.
Coupled amidolytic assay for factor VII: Its use with clotting assay to determine the activity state of factor VII. Blood 1978; 52: 978-988
22
Poggio M,
Tripodi A,
Mariani G,
Mannucci PM.
Factor VII clotting assay: Influence of different thromboplastins and factor VII-deficient plasmas. Thromb Haemost 1991; 65: 160-164
24
Morrissey JH,
Macik BG,
Neuenschwander PF,
Comp PC.
Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-744
25
Wildgoose P,
Nemerson Y,
Hansen LL,
Nielsen FE,
Glazer S,
Hedner U.
Measurement of basal levels of factor Vila in hemophilia A and B patients. Blood 1992; 80: 25-28
28
Dati F,
Barthels M,
Conard J,
Fluckiger J,
Girolami A,
Hanseler E,
Huber J,
Keller F,
Kolde H-J,
Muller-Berghaus G,
Samama M,
Thiel W.
Multicenter evaluation of a chromogenic substrate method for photometric determination of prothrombin time. Thromb Haemost 1987; 58: 856-865
29
Shigematsu Y,
Miyata T,
Higashi S,
Miki T,
Sadler JE,
Iwanaga S.
Expression of human soluble tissue factor in yeast and enzymatic properties of its complex with factor Vila. J Biol Chem 1992; 267: 21329-21337
30
Muller AD,
van Deijk WA,
Devilee PP,
van DarmMieras CE.
The activity state of factor VII in plasma: Two pathways for the cold activation of factor VII. Br J Haematol 1986; 62: 367-377
34
Komiyama Y,
Pedersen AH,
Kisiel W.
Proteolytic activation of human factors IX and X by recombinant factor Vila: effects of calcium, phospholipids, and tissue factor. Biochemistry 1990; 29: 9418-9425
35
Nemerson Y,
Repke D.
Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation cofactor. Thromb Res 1985; 40: 351-358
36
Radcliffe R,
Nemerson Y.
Activation and control of factor VII by activated factor X and thrombin: isolation and characterization of a single chain form of factor VII. J Biol Chem 1975; 250: 388-395
37
Nakagaki T,
Foster DC,
Berkner KL,
Kisiel W.
Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor dependent autoactivation of human coagulation factor VII. Biochemistry 1991; 30: 10819-10824
38
Fiore MM,
Neuenschwander PF,
Morrissey JH.
The biochemical basis for the apparent defect of soluble mutant tissue factor in enhancing the proteolytic activities of factor Vila. J Biol Chem 1994; 269: 143-149
